Payment overview · 2025
General Payments
$2,878.11
49 reported records · 15 companies
Healthcare provider profile · identity verified
Mohammad Aslam, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EAST MEADOW, NY · NPI 1821197708
Verified facts
What the public records show
CMS Open Payments records show Mohammad Aslam, M.D. received $2,878.11 in general payments during 2025 across 49 reported records.
AstraZeneca Pharmaceuticals LP accounted for 43.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Qulipta, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,252.24 | 43.5% | 22 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $373.94 | 13.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $276.86 | 9.6% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $182.16 | 6.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $130.89 | 4.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $124.09 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $123.62 | 4.3% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $122.13 | 4.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $77.31 | 2.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.21 | 2.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.44 | 1.7% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $39.74 | 1.4% | 2 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $22.42 | 0.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $22.14 | 0.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.92 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,878.11 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $615.86 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $465.60 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $373.94 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $182.16 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $170.78 | 8 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $124.77 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $124.09 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $123.62 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $122.13 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $122.13 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $105.15 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $77.31 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $63.21 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.44 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $39.74 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.34 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 98 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 130 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
98 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
130 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
130 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 501 | 153 |
| Metformin Hcl | Metformin Hcl | 392 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 298 | 84 |
| Losartan Potassium | Losartan Potassium | 293 | 91 |
| Simvastatin | Simvastatin | 278 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 86 |
| Fluticasone Propionate | Fluticasone Propionate | 224 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 55 |
| Omeprazole | Omeprazole | 202 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 200 | 51 |
| Lisinopril | Lisinopril | 170 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 44 |
| Gabapentin | Gabapentin | 169 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 44 |
| Glimepiride | Glimepiride | 140 | 40 |
| Jardiance | Empagliflozin | 130 | 28 |
| Furosemide | Furosemide | 122 | 28 |
| Meloxicam | Meloxicam | 115 | 33 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 114 | 47 |
| Fenofibrate | Fenofibrate,micronized | 111 | 37 |
| Januvia | Sitagliptin Phosphate | 109 | 27 |
| Enalapril Maleate | Enalapril Maleate | 102 | 31 |
| Ozempic | Semaglutide | 99 | 23 |
| Farxiga | Dapagliflozin Propanediol | 98 | 28 |
| Alendronate Sodium | Alendronate Sodium | 92 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 25 |
| Carvedilol | Carvedilol | 84 | 28 |
| Naproxen | Naproxen | 83 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 26 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 72 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 22 |
| Famotidine | Famotidine | 66 | 19 |
| Novolog Flexpen | Insulin Aspart | 65 | 22 |
| Meclizine Hcl | Meclizine Hcl | 64 | 22 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 64 | 13 |
| Allopurinol | Allopurinol | 61 | 20 |
| Ramipril | Ramipril | 60 | 13 |
| Trulicity | Dulaglutide | 60 | suppressed |
| Atenolol | Atenolol | 59 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 51 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 13 |
| Fenofibrate | Fenofibrate | 48 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 46 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | suppressed |
| Eliquis | Apixaban | 45 | suppressed |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 45 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 44 | suppressed |
| Linzess | Linaclotide | 42 | suppressed |
| Vascepa | Icosapent Ethyl | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Finasteride | Finasteride | 34 | 11 |
| Mometasone Furoate | Mometasone Furoate | 33 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 14 |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Acarbose | Acarbose | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Comfort Touch Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Alogliptin | Alogliptin Benzoate | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,878.11 · 49 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, FARXIGA, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, NUCALA, NURTEC ODT, OPSUMIT, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UPTRAVI, VOQUEZNA, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error